About Us - GPCR Drug Discovery

HarkerBio was founded in 2014 as a spin-off of the Hauptman-Woodward Medical Research Institute. Our mission is to work with clients to improve and optimize the process of drug discovery through structural biology. We specialize in a variety of services as part of our gene-to-structure pipeline, including protein design, protein production, crystallization, crystallography, and structure determination.

Dr. Artem Evdokimov

Dr. Artem EvdokimovDr. Artem Evdokimov joined HarkerBIO in late July 2015 as Chief Scientific Officer.

Artem received a dual PhD in Chemistry and Structural Biology from the Weizmann Institute of Science in Israel. He then spent two years at the National Institutes of Health (NCI-Frederick in the lab of Dr. David Waugh) where he studied Yersinia pestis, the bacterial pathogen that causes the notorious Bubonic Plague. 

Dr. Evdokimov has worked for Procter & Gamble Pharmaceuticals and Pfizer, where he used structural biology as a tool to assist in the development of potential new treatments for infectious diseases, CNS ailments, cardiovascular conditions and cancer. Most recently he has led a Structure and Design team at Monsanto, where his work enabled the development of novel traits to protect plants against insect predation, to elicit herbicide tolerance, or to enhance yield. To date, Artem has worked on many difficult proteins, resulting in over fifteen issued patent applications, approximately fifty peer-reviewed publications, over one hundred Protein Data Bank (PDB) crystal structure entries, and thousands of structures solved (most of which remain proprietary for now).

Artem's personal web site (not entirely up to date) is www.xtals.org. There you can find a relatively complete list of his publications and Protein Data Bank entries as well as other materials of interest.

Dr. Kristin Sutton

Dr. Kristin SuttonDr. Kristin Sutton received her PhD in Structural Biology from the State University of New York at Buffalo. Her dissertation involved developing a model for Radiation Induced Damage during X-ray data collection. She then spent two years as a Postdoctoral Research Associate at the Hauptman Woodward Medical Research Institute studying the Shikimate Pathway, a potential target for new antibiotics. 


Quick Contact

Monthly Crystallization Screening